422 related articles for article (PubMed ID: 37834246)
21. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
[TBL] [Abstract][Full Text] [Related]
22. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
Xiong J; Bao L; Qi H; Feng Z; Shi Y
Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246
[TBL] [Abstract][Full Text] [Related]
23. Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment.
Raza SS; Khan MA
Cytotherapy; 2022 Aug; 24(8):755-766. PubMed ID: 35880307
[TBL] [Abstract][Full Text] [Related]
24. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
Aitong W; Leisheng Z; Hao Y
Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
[TBL] [Abstract][Full Text] [Related]
25. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
Xu Z; Huang Y; Zhou J; Deng X; He W; Liu X; Li Y; Zhong N; Sang L
Front Immunol; 2021; 12():738697. PubMed ID: 34659231
[TBL] [Abstract][Full Text] [Related]
26. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
[TBL] [Abstract][Full Text] [Related]
27. Clinical progress in MSC-based therapies for the management of severe COVID-19.
Rossello-Gelabert M; Gonzalez-Pujana A; Igartua M; Santos-Vizcaino E; Hernandez RM
Cytokine Growth Factor Rev; 2022 Dec; 68():25-36. PubMed ID: 35843774
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.
Loke XY; Imran SAM; Tye GJ; Wan Kamarul Zaman WS; Nordin F
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830303
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
Grumet M; Sherman J; Dorf BS
Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
Barros I; Silva A; de Almeida LP; Miranda CO
Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
Yadav P; Vats R; Bano A; Bhardwaj R
Life Sci; 2020 Dec; 263():118588. PubMed ID: 33049279
[TBL] [Abstract][Full Text] [Related]
33. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.
Yao W; Shi L; Zhang Y; Dong H; Zhang Y
Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737
[TBL] [Abstract][Full Text] [Related]
34. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
Front Immunol; 2022; 13():932360. PubMed ID: 35860245
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Harrell CR; Jovicic BP; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia.
Hezam K; Mo R; Wang C; Liu Y; Li Z
Curr Pharm Biotechnol; 2022; 23(9):1153-1167. PubMed ID: 34493193
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in mesenchymal stem cell-based therapy for acute lung injury.
Liang J; Dai W; Xue S; Wu F; Cui E; Pan R
Cell Tissue Bank; 2024 Jun; 25(2):677-684. PubMed ID: 38466563
[TBL] [Abstract][Full Text] [Related]
38. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
Mattoli S; Schmidt M
Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
[TBL] [Abstract][Full Text] [Related]
39. Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.
Ngai HW; Kim DH; Hammad M; Gutova M; Aboody K; Cox CD
J Cell Mol Med; 2022 May; 26(9):2483-2504. PubMed ID: 35426198
[TBL] [Abstract][Full Text] [Related]
40. Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial.
Tao YC; Chen EQ
Curr Stem Cell Res Ther; 2024; 19(1):55-62. PubMed ID: 36654468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
